

TCI Gene to enhance Malaysia's preventive healthcare in collaboration with ALPRO pharmacy

28 March 2024 | News

TCI Gene's genetic assessment adopts globally renowned genetic detection points for high-risk diseases



Taiwan-based TCI Gene has announced a strategic partnership with Alpro Pharmacy, a chain pharmacy leader in Malaysia, to exclusively offer its genetic assessment services to Malaysians.

TCI Gene and Alpro Pharmacy aims to provide Malaysians with better preventive healthcare via this initiative, complementing Alpro Pharmacy's objective of comprehensive healthcare. The service, called MyDNA360 in Malaysia, will be available to Malaysians starting the month of April 2024. It offers comprehensive genetic assessment for key critical disorders that matters to majority of Malaysians.

Genetically inherited diseases claim the lives of 1 in 4 Malaysians. In 2020, Malaysia reported 48,639 new cancer cases, equating to 1 cancer case for every 658 Malaysians. Approximately 15% of Malaysians are diagnosed with type 2 diabetes.

According to the Alzheimer's Disease Foundation Malaysia (ADFM), approximately 312% increase in Alzheimer's aging population by 2050. TCI Gene and Alpro Pharmacy believes that genetic testing can empower individuals to take proactive steps towards prevention, rather than waiting until diseases symptoms appear to seek treatment.

TCI Gene's advanced genetic assessment prowess has been recognised by major healthcare providers in Asia. This is a significant milestone in its expansion into the Southeast Asian market.